Jonathon J Graham1,2, Sujit Mukherjee3, Muhammad Yuksel1,4, Rebeca Sanabria Mateos1, Tengfei Si1, Zhenlin Huang1, Xiahong Huang1, Hadil Abu Arqoub5, Vishal Patel1,6, Mark McPhail1, Yoh Zen5, Nigel Heaton1, Maria Serena Longhi2, Michael A Heneghan1, Rodrigo Liberal1, Diego Vergani1, Giorgina Mieli-Vergani7, Yun Ma1, Bu'Hussain Hayee8. 1. Institute of Liver Studies, School of Immunology & Microbial Sciences, Faculty of Life Sciences & Medicine, King's College London, King's College Hospital, London, UK. 2. Department of Anesthesia, Critical Care & Pain Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA. 3. Section of Hepatology, Department of Metabolism Digestion and Reproduction, Faculty of Medicine, Imperial College London, London, UK. 4. Koç University Research Centre for Translational Medicine, Istanbul, Turkey. 5. Liver Histopathology Laboratory, Institute of Liver Studies, King's College London, London, UK. 6. The Roger Williams Institute of Hepatology London, Foundation for Liver Research, London, UK. 7. Paediatric Liver, GI and Nutrition Centre, Mowat Labs, King's College London Faculty of Life Sciences & Medicine at King's College Hospital, London, UK. 8. Department of Gastroenterology, School of Immunology & Microbial Sciences, Faculty of Life Sciences & Medicine, King's College London, King's College Hospital, London, UK.
Abstract
BACKGROUND AND AIMS: The "gut homing" hypothesis suggests the pathogenesis of primary sclerosing cholangitis (PSC) is driven by aberrant hepatic expression of gut adhesion molecules and subsequent recruitment of gut-derived T cells to the liver. However, inconsistencies lie within this theory including an absence of investigations and comparisons with other chronic liver diseases (CLD). Here, we examine "the gut homing theory" in patients with PSC with associated inflammatory bowel disease (PSC-IBD) and across multiple inflammatory liver diseases. APPROACH AND RESULTS: Expression of MAdCAM-1, CCL25, and E-Cadherin were assessed histologically and using RT-PCR on explanted liver tissue from patients with CLD undergoing OLT and in normal liver. Liver mononuclear cells were isolated from explanted tissue samples and the expression of gut homing integrins and cytokines on hepatic infiltrating gut-derived T cells was assessed using flow cytometry. Hepatic expression of MAdCAM-1, CCL25 and E-Cadherin was up-regulated in all CLDs compared with normal liver. There were no differences between disease groups. Frequencies of α4β7, αEβ7, CCR9, and GPR15 expressing hepatic T cells was increased in PSC-IBD, but also in CLD controls, compared with normal liver. β7 expressing hepatic T cells displayed an increased inflammatory phenotype compared with β7 negative cells, although this inflammatory cytokine profile was present in both the inflamed and normal liver. CONCLUSIONS: These findings refute the widely accepted "gut homing" hypothesis as the primary driver of PSC and indicate that aberrant hepatic recruitment of gut-derived T cells is not unique to PSC, but is a panetiological feature of CLD.
BACKGROUND AND AIMS: The "gut homing" hypothesis suggests the pathogenesis of primary sclerosing cholangitis (PSC) is driven by aberrant hepatic expression of gut adhesion molecules and subsequent recruitment of gut-derived T cells to the liver. However, inconsistencies lie within this theory including an absence of investigations and comparisons with other chronic liver diseases (CLD). Here, we examine "the gut homing theory" in patients with PSC with associated inflammatory bowel disease (PSC-IBD) and across multiple inflammatory liver diseases. APPROACH AND RESULTS: Expression of MAdCAM-1, CCL25, and E-Cadherin were assessed histologically and using RT-PCR on explanted liver tissue from patients with CLD undergoing OLT and in normal liver. Liver mononuclear cells were isolated from explanted tissue samples and the expression of gut homing integrins and cytokines on hepatic infiltrating gut-derived T cells was assessed using flow cytometry. Hepatic expression of MAdCAM-1, CCL25 and E-Cadherin was up-regulated in all CLDs compared with normal liver. There were no differences between disease groups. Frequencies of α4β7, αEβ7, CCR9, and GPR15 expressing hepatic T cells was increased in PSC-IBD, but also in CLD controls, compared with normal liver. β7 expressing hepatic T cells displayed an increased inflammatory phenotype compared with β7 negative cells, although this inflammatory cytokine profile was present in both the inflamed and normal liver. CONCLUSIONS: These findings refute the widely accepted "gut homing" hypothesis as the primary driver of PSC and indicate that aberrant hepatic recruitment of gut-derived T cells is not unique to PSC, but is a panetiological feature of CLD.
Authors: Hannah K Drescher; Angela Schippers; Thomas Clahsen; Hacer Sahin; Heidi Noels; Mathias Hornef; Norbert Wagner; Christian Trautwein; Konrad L Streetz; Daniela C Kroy Journal: J Hepatol Date: 2017-02-10 Impact factor: 25.083
Authors: Ingrid Arijs; Gert De Hertogh; Bart Lemmens; Leentje Van Lommel; Magali de Bruyn; Wiebe Vanhove; Isabelle Cleynen; Kathleen Machiels; Marc Ferrante; Frans Schuit; Gert Van Assche; Paul Rutgeerts; Severine Vermeire Journal: Gut Date: 2016-10-07 Impact factor: 23.059
Authors: Kerry A Casey; Kathryn A Fraser; Jason M Schenkel; Amy Moran; Michael C Abt; Lalit K Beura; Philip J Lucas; David Artis; E John Wherry; Kristin Hogquist; Vaiva Vezys; David Masopust Journal: J Immunol Date: 2012-04-13 Impact factor: 5.422
Authors: Thomas Suply; Sébastien Hannedouche; Nathalie Carte; Jianping Li; Bianka Grosshans; Michael Schaefer; Layla Raad; Valérie Beck; Solange Vidal; Agnès Hiou-Feige; Noémie Beluch; Samuel Barbieri; Johann Wirsching; Nadine Lageyre; Frank Hillger; Corinne Debon; Janet Dawson; Philip Smith; Vincent Lannoy; Michel Detheux; Francis Bitsch; Rocco Falchetto; Tewis Bouwmeester; Jeffrey Porter; Birgit Baumgarten; Keith Mansfield; José M Carballido; Klaus Seuwen; Frédéric Bassilana Journal: Sci Signal Date: 2017-09-12 Impact factor: 8.192
Authors: B Christensen; D Micic; P R Gibson; A Yarur; E Bellaguarda; P Corsello; J N Gaetano; J Kinnucan; V L Rao; S Reddy; S Singh; J Pekow; D T Rubin Journal: Aliment Pharmacol Ther Date: 2018-01-29 Impact factor: 8.171
Authors: Christopher A Lamb; John C Mansfield; Gaik W Tew; Deena Gibbons; Anna K Long; Peter Irving; Lauri Diehl; Jeff Eastham-Anderson; Maria B Price; Graeme O'Boyle; David E J Jones; Sharon O'Byrne; Adrian Hayday; Mary E Keir; Jackson G Egen; John A Kirby Journal: J Crohns Colitis Date: 2017-05-01 Impact factor: 9.071
Authors: Angela Schippers; Jessica Hübel; Felix Heymann; Thomas Clahsen; Sreepradha Eswaran; Sarah Schlepütz; Robin Püllen; Nikolaus Gaßler; Klaus Tenbrock; Frank Tacke; Norbert Wagner Journal: Cell Mol Gastroenterol Hepatol Date: 2020-12-13
Authors: Sebastian Zundler; Claudia Günther; Andreas E Kremer; Mario M Zaiss; Veit Rothhammer; Markus F Neurath Journal: Nat Rev Gastroenterol Hepatol Date: 2022-08-09 Impact factor: 73.082